Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy

Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy

kidneycancer

6 months
38 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department - Oncoclínicas/HSL-PUCRS Visiting Scientist at Dana-Farber Cancer Institute/ Harvard Medical School discusses
Optimal Management of Favorable Risk Clear Cell RCC Combination Therapy at the 18th International Kidney Cancer Symposium 2019, Miami, FL.



Up Next Autoplay